Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) has just exploded in trading volume and popped in price. Shares as of 12:55 PM EST have seen 1.065 million shares trade hands, and the gain in 17% at $1.68. Angiotech’s 52-week range is $0.10 to $3.00 and it trades an average of 2.5 million shares per day.
NEWS: While this was an expected an FDA approval, the company did announce that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has received FDA approval to mart its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System. This is the next-generation drug-eluting stent (DES) designed for long lesions that measures 38 mm and can potentially reduce the number of stents used in more Byzantine cases.
JON C. OGG
JULY 16, 2009 at 12:55 PM EST.
No comments:
Post a Comment